Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05913882

Combined Respiratory Training in Persons With ALS

Combined Respiratory Training to Improve Pulmonary and Cough Function in Persons With ALS

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
34 (estimated)
Sponsor
Nova Southeastern University · Academic / Other
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

The goal of this interventional trial is to learn about lung volume recruitment (LVR) and expiratory muscle strength training (EMST) in a total of up to 39 patients diagnosed with ALS. The following aims will be addressed: 1. Determine the impact of combined LVR and EMST on cough strength and respiratory function in individuals with ALS. 2. Determine the impact of combined LVR and EMST on patient-reported dyspnea and bulbar impairment. 3. Describe the effect of combined LVR and EMST on patient- and caregiver reported burden and quality of life.

Detailed description

In this delayed start, repeated-measures design, pALS will serve as their own control to provide treatment to all participants and control for disease heterogeneity (i.e., interparticipant differences). Participation will include three in-person evaluations and four weekly telehealth therapy sessions (Figure 3). Weekly telehealth therapy sessions will include home peak cough flow assessment, LVR and EMST training sessions to ensure treatment fidelity, maximum phonation time as a surrogate measure of forced vital capacity, and patient-reported outcomes including the ALS Respiratory Symptom Scale. To assess peak cough flow at home, participants will be provided with a commercially available peak cough flow meter (MiniWright, PF100) for guided assessment during telehealth appointments. Study Timeline. Study assessments and procedures at each time point are briefly described below and depicted in Table 1. Screening/Baseline 1 (Week -5). Following consenting and screening procedures, study personnel will complete the initial baseline assessment procedures. Participants will complete the initial baseline assessment in approximately 60-90 minutes. Baseline 2 (Week 0). The Baseline 2 appointment will consist of the identical assessment procedures conducted in the same order as Baseline 1. LVR and EMST training will be introduced and the first training session will be completed during the appointment. Participants will complete the Baseline 2 appointment in \~100-120 minutes. Telehealth Appointments (Active Training Weeks 0-5). Weekly telehealth therapy appointments will be conducted during the active training period using the Zoom platform (Zoom Video Communications, Inc). During these sessions, the research clinician will lead a LVR and EMST training session with the participant, complete peak cough flow and maximum sustained phonation testing, and administered surveys including the ALS Functional Rating Scale- Revised and the ALS Respiratory Symptom Scale. Surveys will be screen shared with the participants and data will be recorded on the source documents by the research clinician. Final Evaluation (Week 5). The Final Evaluation appointment will consist of the identical assessment procedures conducted in the same order as Baseline 2. Follow-up Period (6-months). The follow-up period consists of monthly telehealth visits with the research clinician. Participants who complete the initial 10-week study period will be asked to participate in follow-up. These telehealth visits will include peak cough flow and maximum phonation time assessments, and clinician-administered surveys. During this period, treatment adherence will be tracked using the same daily treatment logs, which will be reviewed during monthly appointments.

Conditions

Interventions

TypeNameDescription
DEVICERespiratory Muscle Strength Training (LVR+EMST)Combined respiratory muscle strength training regimen that will be completed daily for 5 weeks.

Timeline

Start date
2023-08-22
Primary completion
2026-09-30
Completion
2026-09-30
First posted
2023-06-22
Last updated
2025-12-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05913882. Inclusion in this directory is not an endorsement.